What is B. Riley's Forecast for LifeMD Q4 Earnings?

Key Points

• LifeMD, Inc. is projected to earn $0.22 per share in Q4 2026, while the current consensus estimate for the full year stands at ($0.56) per share.
• Recently, analysts have issued mixed ratings on LifeMD, with a consensus target price of $12.86 and most ratings falling between "buy" and "hold."
• The company's stock traded up 2.6% to $6.78, with institutional investors holding approximately 35.52% of the stock.

LifeMD, Inc. (NASDAQ:LFMD - Free Report) - Investment analysts at B. Riley issued their Q4 2026 earnings estimates for LifeMD in a research note issued to investors on Wednesday, August 6th. B. Riley analyst A. Schock expects that the company will post earnings of $0.22 per share for the quarter. The consensus estimate for LifeMD's current full-year earnings is ($0.56) per share.

A number of other equities analysts have also recently commented on LFMD. Lake Street Capital reduced their price objective on shares of LifeMD from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, August 6th. BTIG Research boosted their target price on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Wednesday, June 18th. HC Wainwright reduced their target price on shares of LifeMD from $14.00 to $13.00 and set a "buy" rating for the company in a research report on Thursday, August 7th. KeyCorp reduced their target price on shares of LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a research report on Wednesday, August 6th. Finally, Wall Street Zen cut shares of LifeMD from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $12.86.

LifeMD Stock Performance

LFMD stock traded up $0.11 during midday trading on Friday, reaching $6.83. 2,621,004 shares of the company were exchanged, compared to its average volume of 1,671,861. The company has a debt-to-equity ratio of 9.21, a current ratio of 0.77 and a quick ratio of 0.72. The business has a 50-day moving average price of $11.74 and a two-hundred day moving average price of $8.53. LifeMD has a one year low of $3.99 and a one year high of $15.84. The firm has a market capitalization of $323.88 million, a price-to-earnings ratio of -32.52 and a beta of 1.72.

Institutional Trading of LifeMD

Several institutional investors and hedge funds have recently modified their holdings of LFMD. Wealth Enhancement Advisory Services LLC acquired a new position in LifeMD during the fourth quarter worth about $56,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LifeMD by 17.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,412 shares of the company's stock valued at $235,000 after buying an additional 7,001 shares during the period. Northern Trust Corp increased its position in LifeMD by 2.1% during the 4th quarter. Northern Trust Corp now owns 323,974 shares of the company's stock valued at $1,604,000 after purchasing an additional 6,634 shares during the period. Price T Rowe Associates Inc. MD increased its position in LifeMD by 26.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after purchasing an additional 2,895 shares during the period. Finally, BNP Paribas Financial Markets acquired a new stake in LifeMD during the 4th quarter valued at approximately $279,000. 35.52% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Justin Schreiber sold 25,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $13.38, for a total transaction of $334,500.00. Following the completion of the sale, the chief executive officer owned 2,500,721 shares of the company's stock, valued at $33,459,646.98. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Eric Harold Yecies sold 15,000 shares of the company's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $12.25, for a total transaction of $183,750.00. Following the sale, the insider directly owned 16,100 shares of the company's stock, valued at $197,225. This represents a 48.23% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 275,000 shares of company stock worth $3,564,550. 18.40% of the stock is owned by company insiders.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.